BD partners with US on $19 billion manufacturing investment

• BD (NYSE:BDX) announced a multi-year partnership with the U.S. government to expand domestic production of medical consumables.
• The medical technology firm intends to invest $19 billion across U.S. operations, including $3 billion dedicated to manufacturing facilities.
• The strategic initiative aims to raise domestic production to 80% of U.S. supply and source 100% of needle steel domestically.

BD (NYSE:BDX) partnered with the U.S. government to expand domestic manufacturing and supply chain infrastructure for critical medical consumables.

The initiative seeks to strengthen domestic healthcare supply chains by adding approximately 5 billion U.S.-produced medical consumables annually.

The agreement provides relief from future Section 232 tariffs on covered products and inputs, subject to the final scope and implementation of those actions and achievement of agreed milestones.

The company confirmed that 100% of its needles sold in the U.S. will be manufactured domestically using American-made steel.

BD manufactures and distributes medical supplies, laboratory equipment, and diagnostic devices across international healthcare markets.

Management noted that final tariff rates, scope, and timing remain undetermined, and the company is not currently quantifying the financial impact.